Vera Therapeutics Statistics
Share Statistics
Vera Therapeutics has 63.77M
shares outstanding. The number of shares has increased by 16.54%
in one year.
| Shares Outstanding | 63.77M |
| Shares Change (YoY) | 16.54% |
| Shares Change (QoQ) | 0.67% |
| Owned by Institutions (%) | 99.99% |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 20,819 |
| FTD / Avg. Volume | 2.05% |
Short Selling Information
The latest short interest is 7.07M, so 11.08% of the outstanding
shares have been sold short.
| Short Interest | 7.07M |
| Short % of Shares Out | 11.08% |
| Short % of Float | 12.77% |
| Short Ratio (days to cover) | 4.65 |
Valuation Ratios
The PE ratio is -15.38 and the forward
PE ratio is -5.53.
Vera Therapeutics's PEG ratio is
-0.69.
| PE Ratio | -15.38 |
| Forward PE | -5.53 |
| PS Ratio | 0 |
| Forward PS | 1.6 |
| PB Ratio | 4.05 |
| P/FCF Ratio | -17.25 |
| PEG Ratio | -0.69 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for Vera Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 25.67,
with a Debt / Equity ratio of 0.09.
| Current Ratio | 25.67 |
| Quick Ratio | 25.67 |
| Debt / Equity | 0.09 |
| Debt / EBITDA | -0.33 |
| Debt / FCF | -0.4 |
| Interest Coverage | -21.92 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,000,973.68 |
| Employee Count | 152 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 1K |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -45.93% in the
last 52 weeks. The beta is 1.28, so Vera Therapeutics's
price volatility has been higher than the market average.
| Beta | 1.28 |
| 52-Week Price Change | -45.93% |
| 50-Day Moving Average | 22.66 |
| 200-Day Moving Average | 35.2 |
| Relative Strength Index (RSI) | 40.24 |
| Average Volume (20 Days) | 1,017,431 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -167.17M |
| Net Income | -152.15M |
| EBITDA | -167.17M |
| EBIT | -159.77M |
| Earnings Per Share (EPS) | -2.75 |
Full Income StatementBalance Sheet
The company has 92.65M in cash and 54.64M in
debt, giving a net cash position of 38.01M.
| Cash & Cash Equivalents | 92.65M |
| Total Debt | 54.64M |
| Net Cash | 38.01M |
| Retained Earnings | -461.25M |
| Total Assets | 610.17M |
| Working Capital | 584.18M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -134.68M
and capital expenditures -972K, giving a free cash flow of -135.65M.
| Operating Cash Flow | -134.68M |
| Capital Expenditures | -972K |
| Free Cash Flow | -135.65M |
| FCF Per Share | -2.45 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
